ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting (POTASSIUM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01392534
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : July 4, 2012
Sponsor:
Information provided by:
Bayer

Brief Summary:
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion. Disregulation of plasma potassium may be a life-threatening condition due to increased risk of arrythmias. Moreover, it has been postulated that decrease in plasma potassium level may negatively affect glucose metabolism resulting in the increased risk of new-onset type 2 diabetes.The main goal of this study is to assess the efficacy and safety of telmisartan/hydrochlorothiazide in a broad population of hypertensive patients, including the effects of the therapy on plasma potassium level and also on selected parameters of glucose and lipid metabolism.

Condition or disease Intervention/treatment
Primary Hypertension Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)

Study Type : Observational
Actual Enrollment : 1586 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Real-life Efficacy and Safety of a Fixed-dose Telmisartan/Hydrochlorothiazide, Including Its Effect on Plasma Potassium and on Glucose and Lipid Metabolism Parameters in Patients With Essential Arterial Hypertension
Study Start Date : July 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Potassium
U.S. FDA Resources

Group/Cohort Intervention/treatment
Group 1 Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment



Primary Outcome Measures :
  1. Change in systolic (SBP) and diastolic (DBP) blood pressure between first and final visit [ Time Frame: approx. 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]

Secondary Outcome Measures :
  1. Change in plasma potassium between initial and final visit [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  2. Change in fasting plasma glucose between initial and final visit [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  3. Change in glycated haemoglobin A1C between initial and final visit [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  4. Change in plasma high density lipoprotein between initial and (continued) [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  5. Change in plasma low density lipoprotein between initial and final visit [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  6. Change in plasma cholesterol between initial and final visit [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  7. Change in plasma triglycerides between initial and final visit [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]
  8. Adverse events collection [ Time Frame: approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic hypertensive patients not treated with telmisartan/hydrochlorothiazide for approx. 3 mths.
Criteria

Inclusion Criteria:

  • primary hypertension
  • age>18 years

Exclusion Criteria:

  • Cholestatic disorders or severe hepatic/renal failure
  • allergy to telmisartan or hydrochlorothiazide
  • treatment-resistant hypokalemia or hypercalcemia
  • pregnancy and lactation period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01392534


Locations
Poland
Many Locations, Poland
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Medical Director, Bayer Sp. z o.o. , Poland
ClinicalTrials.gov Identifier: NCT01392534     History of Changes
Other Study ID Numbers: 15297
KL1010PL ( Other Identifier: Company Internal )
First Posted: July 12, 2011    Key Record Dates
Last Update Posted: July 4, 2012
Last Verified: July 2012

Keywords provided by Bayer:
Hypertension
Telmisartan
Hydrochlorothiazide
Potassium
Glucose metabolism
Lipid metabolism

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Hydrochlorothiazide
Antihypertensive Agents
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists